Developers are increasingly exploring non-viral delivery systems for gene therapy as safety concerns over viral vectors mount, including patient deaths linked to liver toxicity. While non-viral ...
The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...
The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...
Researchers addressed the need for long-term expression of CCR5-specific antibodies to establish protection from HIV using ...
Three 2026 Breakthrough Prize winners reflect on developing Luxturna, a gene therapy that treats blindness caused by rare ...
Viralgen continues its pioneering work in manufacturing science with advancements in key process understanding with analytical tools ...
Heart diseases are still the number one cause of death worldwide. According to the World Health Organization, cardiovascular diseases led to the deaths of about 9.8 million people in 2022 alone, ...
Preliminary findings from the pivotal cohort showed that the CR rate was 71% at any time, 67% at 3 months, and 47% at 6 months. The Food and Drug Administration (FDA) has granted Regenerative Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results